Hodgkin Lymphoma Clinical Trials

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20831
A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); EPZ-6438 (Tazemetostat); Lenalidomide (Revlimid); Rituxan (rituximab); Tazemetostat (); Tazemetostat/Placebo (); rituximab ()

CLINICAL TRIAL 21122
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: AZD0486 (); TNB-486 ()

CLINICAL TRIAL 21710
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitabmab in Combination with CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: CC-99282 (); Glofitamab (); Mosunetuzumab (); Tocilizumab ()

CLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Condition: Multiple
Intervention:

CLINICAL TRIAL 21892
A Phase 2, Single-Arm, Open-Label Study using Oral JAK inhibition as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Condition: Malignant Hematology
Intervention: Anakinra (); Axicabtagene Ciloleucel (Yescarta); Itacitinib (); Jakafi (Ruxolitinib); Ruxolitinib (); Tafasitamab (); Tocilizumab (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 21955
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma after Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Tafasitamab ()

CLINICAL TRIAL 22005
A Phase 2 Open-Label, Multicenter Study of Rituximab and Zanubrutinib in Patients with indolent B-cell Lymphomas
Condition: Malignant Hematology
Intervention: Rituxan (rituximab); Rituximab Subq (); Zanubrutinib (); rituximab ()

CLINICAL TRIAL 22080
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: Adriamycin (doxorubicin); Axicabtagene Ciloleucel (Yescarta); Etoposide (); Rituxan (rituximab); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); fludarabine (Fludarabine phosphate); prednisone (); rituximab ()

CLINICAL TRIAL 22113
Phase 2, Single-Arm Trial of Comprehensive Ablative Bridging Irradiation (CABI) Prior to CD19 CAR-T Cell Therapy in Relapsed or Refractory Large B Cell Lymphoma in Patients
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (Yescarta); Radiotherapy (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22263
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or B-cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: AS-1763 ()

CLINICAL TRIAL 22557
A Phase 2, Open-Label, Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Condition: Malignant Hematology
Intervention: CD19 CAR T Cells (); Pirtobrutinib ()

CLINICAL TRIAL 23184
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy (CARIsMA)
Condition: Malignant Hematology
Intervention: Placebo ()

CLINICAL TRIAL 23198
CCT5065: Optimizing ctDNA-based MRD assessment in DLBCL, MCL, and FL patients undergoing CAR Therapy
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23652
A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Condition: Malignant Hematology
Intervention: Rapamycin (Sirolimus); UB-VV111 ()

CLINICAL TRIAL 23320
A Phase 2, Open-label, Multicenter Study of MB-105 in Patients with CD5 Positive (CD5+) Relapsed/Refractory T-cell Lymphoma (r/r TCL)
Condition: Malignant Hematology
Intervention: MB-105 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23331
A Phase 3 study to evaluate safety and efficacy of the combination of for Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral T-Cell Lymphoma (blood cancer) patients
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23422
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Condition: Malignant Hematology
Intervention: Not Applicable ()

CLINICAL TRIAL 23363
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)
Condition: Malignant Hematology
Intervention: ALLO-647 (); Cema-cel (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23489
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23502
BMT-CARE: Multimodal Psychosocial Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23455
A phase I/IB study of Ropeginterferon in patients with Cutaneous T-Cell Lymphoma (CTCL)
Condition: Malignant Hematology
Intervention: Ropeginterferon alfa-2b (P1101) ()

CLINICAL TRIAL 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 23547
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogenic CAR-T Cell Therapy, in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma(T-RRex)
Condition: Malignant Hematology
Intervention: WU-CART-007 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23570
Feasibility of Dietary Interventions for Optimizing CAR-T Cell Function in Cancer Patients and Adults without Cancer
Condition: Multiple
Intervention:

CLINICAL TRIAL 23706
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (Yescarta)

CLINICAL TRIAL 23735
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Condition: Malignant Hematology
Intervention: lisocabtagene maraleucel ()